Venmax Drugs & Pharmaceuticals Current Share Price | Venmax Drugs & Pharmaceuticals Stock Screener
VENMAX
Pharmaceuticals
Venmax Drugs & Pharmaceuticals Current Stock Price Today
Live Share Price BSE
₹16.73
▲
0.27 (1.64%)
As of August 18, 2026, the live Venmax Drugs & Pharmaceuticals share price (BSE: VENMAX) is ₹16.73, up 1.64% from the previous close, with shares trading between ₹16.54 and ₹17.99 in today's trading session, and a 52-week range of ₹15.94–₹35.29.
Analyse VENMAX price movement history and track historical price performance.
Use the Venmax Drugs & Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Venmax Drugs & Pharmaceuticals Market Cap
₹25.32 Cr.
VENMAX P/E Ratio (TTM)
89.11
Venmax Drugs & Pharmaceuticals P/B Ratio
1.18
EPS (TTM)
₹0.21
Dividend Yield
-
Debt to Equity
0.11
VENMAX 52 Week High
₹35.29
Venmax Drugs & Pharmaceuticals 52 Week Low
₹15.94
Operating Margin
2.00%
Profit Margin
-
VENMAX Revenue (TTM)
₹9.00
EBITDA
-
Net Income
-
Total Assets
₹16.00
Total Equity
₹14.00
Venmax Drugs & Pharmaceuticals Current Share Price Chart
Track the current Venmax Drugs & Pharmaceuticals share price and stock price with an interactive chart. Analyse VENMAX price trends, trading volume, historical performance, and volatility across different timeframes — the complete Venmax Drugs & Pharmaceuticals stock quote in one place.
Venmax Drugs & Pharmaceuticals Company Profile - Fundamental Screener
Screen Venmax Drugs & Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VENMAX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE154G01022
Venmax Drugs & Pharmaceuticals Balance Sheet Screener
Screen VENMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Current Assets | 16 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 14 | 4 | -1 | -1 | -1 | -3 | -3 | -2 | -2 | -2 |
| Share Capital | 12 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 3 | -6 | -6 | -6 | -6 | -8 | -8 | -8 | -7 | -7 |
Venmax Drugs & Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Venmax Drugs & Pharmaceuticals income statement and profit fundamentals.
Analyze VENMAX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Venmax Drugs & Pharmaceuticals share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 8 | 2 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 2 |
| Expenses | 9 | 8 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 3 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Operating Profit % | 2.00% | 2.00% | -131.00% | 0.00% | 0.00% | 0.00% | -198.00% | -54.00% | -158.00% | 0.00% | -238.00% | -7.00% | -5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| EPS | 0.40 | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 | -0.31 | -0.52 | -0.45 | -0.46 | -2.55 | -0.26 | -0.15 |
Venmax Drugs & Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen VENMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 5 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Net Cash Flow | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Venmax Drugs & Pharmaceuticals Shareholding Pattern Screener
See Venmax Drugs & Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Venmax Drugs & Pharmaceuticals promoter holding and ownership changes for VENMAX on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 13.80% | 10.46% | 23.14% | 23.14% | 23.14% | 15.14% | 23.14% | 23.14% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.15% | 0.00% | 0.00% | 0.00% | 0.15% | 0.15% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 66.29% | 74.34% | 65.24% | 65.01% | 65.36% | 64.25% | 65.66% | 65.66% |
| Other Holding | 19.91% | 15.20% | 11.47% | 11.86% | 11.51% | 20.61% | 11.06% | 11.06% |
| Shareholder Count | 6,802 | 6,865 | 6,756 | 6,729 | 6,764 | 6,815 | 6,251 | 6,252 |
Venmax Drugs & Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Venmax Drugs & Pharmaceuticals dividend history with payout and yield data.
View Venmax Drugs & Pharmaceuticals dividend details including ex-dates and amounts for VENMAX stock.
Venmax Drugs & Pharmaceuticals Stock Index Membership
See which indices include Venmax Drugs & Pharmaceuticals stock.
Check VENMAX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Venmax Drugs & Pharmaceuticals Market Events Screener - Corporate Actions
Get Venmax Drugs & Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Venmax Drugs & Pharmaceuticals stock events that may affect VENMAX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 4.08% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 6.42% |
| 2026-02-07 | 2026-02-07 | Quarterly Result Announcement | NA | 14.82% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 6.31% |
| 2025-09-27 | 2025-09-27 | Annual General Meeting | NA | -26.93% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | 13.02% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | -2.05% |
| 2025-02-06 | 2025-02-06 | Extraordinary General Meeting | NA | 39.43% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 0.00% |
| 2024-09-21 | 2024-09-21 | Annual General Meeting | NA | 0.00% |
Venmax Drugs & Pharmaceuticals Competitors Screener - Peer Comparison
Screen VENMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,595 | 38.12 | 61,674 | 12.69% | 11,565 | 47.09 |
| Divis Laboratories | 224,480 | 77.15 | 11,067 | 13.95% | 2,568 | 71.85 |
| Torrent Pharmaceuticals | 186,380 | 85.40 | 13,886 | 20.34% | 2,138 | 45.42 |
| Cipla | 115,643 | 34.91 | 29,045 | 2.24% | 3,870 | 50.74 |
| Zydus Life Science | 113,704 | 24.76 | 27,658 | 17.64% | 5,026 | 50.68 |
| Lupin | 103,335 | 18.41 | 29,039 | 26.75% | 5,356 | 30.04 |
| Dr Reddys Laboratories | 99,493 | 31.52 | 35,059 | 3.90% | 4,158 | 49.18 |
| Mankind Pharma | 97,921 | 48.34 | 14,636 | 14.85% | 1,938 | 43.34 |
| Laurus Labs | 97,698 | 89.94 | 6,868 | 22.01% | 890 | 61.64 |
| Aurobindo Pharma | 93,700 | 25.95 | 34,145 | 5.56% | 3,503 | 55.68 |
Venmax Drugs & Pharmaceuticals Company Announcements - News Screener
Screen VENMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Statement Of Deviation & Variation | - |
| 2026-08-10 | Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-08-10 | Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-08-01 | Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-07-29 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-27 | Closure of Trading Window | - |
| 2026-05-15 | Statement Of Deviation & Variation | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-14 | Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-14 | Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-06 | Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31 2026. | - |
| 2026-04-14 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-14 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-06 | Regulation 31(4) - SAST Disclosure | - |
| 2026-03-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-27 | Board Meeting Outcome for Modification Of Draft Scheme Of Amalgamation | - |